Literature DB >> 8878616

In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.

H M Wardle1, D Law, D W Denning.   

Abstract

We compared the in vitro activity of BMS-181184, the first compound of a new class of antifungal agents, the pradimicins, with those of fluconazole and amphotericin B against 64 clinical isolates of Candida species. MICs were determined by a microdilution method with high resolution medium for BMS-181184 and fluconazole and antibiotic medium no. 3 with 2% glucose for amphotericin B. MICs of BMS-181184 for all yeasts were in the range of 0.78 to 12.5 micrograms/ml. BMS-181184 was active against isolates resistant to other antifungal agents, consistent with a novel mode of action. Minimum fungicidal concentrations for 16 isolates showed that BMS-181184 was fungicidal. Clinical studies are now required to confirm its activity.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8878616      PMCID： PMC163508     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Calcium-dependent anticandidal action of pradimicin A.

Authors:  Y Sawada; K Numata; T Murakami; H Tanimichi; S Yamamoto; T Oki
Journal:  J Antibiot (Tokyo)       Date:  1990-06       Impact factor: 2.649

2.  High prevalence of antifungal resistance in Candida spp. from patients with AIDS.

Authors:  D Law; C B Moore; H M Wardle; L A Ganguli; M G Keaney; D W Denning
Journal:  J Antimicrob Chemother       Date:  1994-11       Impact factor: 5.790

3.  Fluconazole resistance in Candida glabrata.

Authors:  C A Hitchcock; G W Pye; P F Troke; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

4.  Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period.

Authors:  M F Price; M T LaRocco; L O Gentry
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

5.  Fluconazole-resistant candidosis in an HIV cohort.

Authors:  G G Baily; F M Perry; D W Denning; B K Mandal
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

6.  Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.

Authors:  E M Johnson; D W Warnock; J Luker; S R Porter; C Scully
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

7.  Fluconazole-resistant Candida albicans.

Authors:  D J Boken; S Swindells; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

8.  In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp.

Authors:  H M Wardle; D Law; C B Moore; C Mason; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191
  8 in total
  2 in total

Review 1.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

Review 2.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.